Updated May 2026
Foundayo vs Saxenda
Side-by-side comparison of Foundayo (orforglipron) and Saxenda (liraglutide (daily injection)) across efficacy, food restrictions, monthly cost, and Medicare Bridge coverage.
Our pick for most patients
Foundayo
Based on the data below, Foundayo wins on covered under the Medicare GLP-1 Bridge ($50/mo from Jul 1, 2026). Your situation may differ — try the personalized matcher on the homepage or compute your real out-of-pocket with the cost calculator on each medication's detail page.
| Field | Foundayo | Saxenda |
|---|---|---|
| Route | tablet · daily | injection · daily |
| Avg weight loss | 12–16% | 5–8% |
| Food restriction | No food OR water | No food restriction |
| Cash from | $149/mo | $1349/mo |
| Savings card | $25/mo | — |
| Medicare Bridge | $50/mo ✓ | Tier 4 |
| A1c reduction | — | — |
| FDA approved | 2026-04 | 2014-12 |
- RouteFoundayotablet · dailySaxendainjection · daily
- Avg weight lossFoundayo12–16%Saxenda5–8%
- Food restrictionFoundayoNo food OR waterSaxendaNo food restriction
- Cash fromFoundayo$149/moSaxenda$1349/mo
- Savings cardFoundayo$25/moSaxenda—
- Medicare BridgeFoundayo$50/mo ✓SaxendaTier 4
- A1c reductionFoundayo—Saxenda—
- FDA approvedFoundayo2026-04Saxenda2014-12
Pick Foundayo if…
- You can't reliably do a fasting window before meds
- You're on Medicare and want the $50/mo Bridge price
- Cash pay matters more than peak weight loss ($149/mo cheaper)
- You're needle-averse
- You want the higher peak efficacy (16% vs 8%)
Pick Saxenda if…
- You can't reliably do a fasting window before meds
Not sure which fits?
The 30-second matcher on the homepage scores every 2026 GLP-1 against your goals + preferences and recommends the best fit.